NCT05451849 · MORE INFO

Limitations, agreements, and source contact

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer · Source last updated 2026-07-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

limitations And Caveats

description: Due to the lack of a clear signal of robust clinical activity during Phase 1, the study was terminated early and Phase 2 was not initiated. Dose-limiting toxicity and recommended Phase 2 dose determination were not performed.

point Of Contact

Complete source fields

certain Agreement

limitations And Caveats

description: Due to the lack of a clear signal of robust clinical activity during Phase 1, the study was terminated early and Phase 2 was not initiated. Dose-limiting toxicity and recommended Phase 2 dose determination were not performed.

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice